 |
 |
 |
 |
 |
 |
 |
Member Information
Ian Frank , MD
Associate Professor, Infectious Diseases
Office Phone: 215-662-7419
Office Fax:
Email: franki@mail.med.upenn.edu
Website(s): http://www.uphs.upenn.edu/idd/10.html
Education: MD 1980, Dartmouth Hospital
Keywords: Antiretroviral therapy, clinical trials, lipodystrophy, resistance
Research and/or Clinical Interests:
Antiretroviral treatment strategies, complications of antiretroviral therapy, and the use of antiretroviral therapy to understand HIV pathogenesis
Summary:
Antiretroviral therapy has dramatically changed the course of the HIV epidemic, prolonging life and reducing morbidity. However, antiretroviral resistance is common and complications are frequent, requiring alternative treatment strategies and a greater understanding of the etiology and risk factors associated with complications of antiretroviral therapy in order to maintain long-term immunological and clinical benefits.
To meet these challenges, the following studies are underway:
A multicenter trial comparing restoration of immune function and resetting of the viral load set point following antiretroviral treatment interruption, vaccination with a multivalent canarypox vaccine, or both. The impact of these interventions on the latently infected cell reservoir and genital tract compartment is being analyzed.
A study of the association between body fat redistribution and insulin resistance and dyslipidemia in patients on protease inhibitor-inclusive and -sparing antiviral combinations, and the effect of treatment on adipocyte gene expression.
A study of lipoprotein kinetics in patients on antiretroviral therapy
An analysis of the risks for dyslipidemia associated with polymorphisms in host genetics
Studies of new antiretroviral agents, including novel entry inhibitors and protease inhibitors.
Representative Publications:
Nunnari G, Otero M, Dornadula G, Vanella M, Zhang H, Frank I, and Pomerantz P: Residual HIV-1 disease in seminal cells of HIV-1 infected men on suppressive HAART: latency without on-going cellular infections. AIDS 16:39-45, 2002.
Chen W, Sulcove J, Frank I, Jaffer S, Ozdener H and Kolson DL: Development of a human neuronal cell model for HIV/macrophage-induced neurotoxicity: apoptosis induced by HIV-1 primary isolates and evidence for involvement of the Bcl-2/Bcl-xL-sensitive intrinsic apoptosis pathway. Journal of Virology. 76:9407-9419, 2002.
Frank I: Once-daily HAART: toward a new treatment paradigm. Journal of Acquired Immune Deficiency Syndromes. 31S10-15, 2002.
Frank I: Antivirals against HIV-1. Clinics in Laboratory Medicine. 22:741-757, 2002.
Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi J-P, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, and Kuritzkes DR for the AIDS Clinical Trials Group 347 Study Team: Treatment with amprenavir with or without zidovudine plus lamivudine in adults with human immunodeficiency virus infection. Journal of Infectious Diseases. 179:808-16, 1999.
Yi Y, Isaacs SN, Williams DA, Frank I, Schols D, De Clerq E, Kolson DL, and Collman RG: Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. Journal of Virology. 73:7117-7125, 1999.
Ziegner U, Campbell D, Weinhold K, Frank I, Rutstein R, and Starr SE: Deficient antibody-dependent cellular cytotoxicity (ADCC) against human immunodeficiency virus (HIV) - expressing target cells in perinatal HIV infection. Clinical and Diagnostic Laboratory Immunology. 6:718-724, 1999.
Frank I: Complications of HIV Infection. In: Lanken P, Manaker C, Hanson CW III, eds. The Intensive Care Unit Manual. Philadelphia : WB Saunders Co. In press.
Frank I: Clinical use of hydroxyurea in HIV infected patients. Journal of Biological Response Modifiers and Homeostatic Agents. In press.
